"Eli Lilly's Diabetes Drug Mounjaro Skyrockets, Boosting Stock by 652%"

Eli Lilly's stock (LLY) surged after the drugmaker reported "explosive" growth in sales for its diabetes blockbuster drug Mounjaro, which saw a 652% increase in sales in the September quarter. The strong performance of Mounjaro, along with the breast cancer drug Verzenio, contributed to Lilly's overall sales of $9.5 billion, beating expectations. However, the company's adjusted earnings tumbled 95% due to expected tax charges. Lilly also cut its adjusted earnings guidance for the year and delayed the FDA decision on its potential Alzheimer's treatment.